Anders Fink-Jensen
Mental Healt h Service Centre Copenhagen , Frederiksberg Hospital, NP Lab · Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Psychiatric Center Copenhagen, Frederiksberg Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anders Fink-Jensen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:59 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06939088 · Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use DisorderAnders Fink-Jensen, MD, DMSci · recruiting · Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence · principal investigator
- Ph2NCT05895643 · Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?Psychiatric Centre Rigshospitalet · completed · Alcohol Abuse, Alcohol Addiction, Alcohol Dependence · principal investigator
- Ph2NCT05416229 · Psilocybin-assisted Therapy for Treatment of Alcohol Use DisorderAnders Fink-Jensen, MD, DMSci · completed · Alcohol Use Disorder · principal investigator
- Ph4NCT04892199 · Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?Anders Fink-Jensen, MD, DMSci · unknown · Metabolic Disturbance, Schizophrenia, Type 2 Diabetes · principal investigator
- Ph2NCT04718792 · Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility StudyAnders Fink-Jensen, MD, DMSci · unknown · Alcohol Use Disorder (AUD) · principal investigator
- N/ANCT03878225 · Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans?Anders Fink-Jensen, MD, DMSci · unknown · Alcohol Use Disorder, Alcohol Withdrawal, Ketosis · principal investigator
- Ph4NCT02625103 · The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring.Anders Fink-Jensen, MD, DMSci · completed · Schizophrenia · principal investigator
- Ph2NCT01845259 · Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?Psychiatric Centre Rigshospitalet · unknown · Impaired Glucose Tolerance Associated With Drugs · principal investigator
- Ph4NCT01119014 · Tolerance and Effect of Antipsychotics in Children and Adolescents With PsychosisAnne Katrine Pagsberg · completed · Psychosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:59 UTC. The ranking covers the 200 most relevant of 26 PubMed records, and a shared surname and initials can bring in a namesake. All 26 on PubMed
- Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.JCI Insight · 2022225 citationsRCR 19.7
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.JAMA Psychiatry · 2017188 citationsRCR 8.2
- Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.JAMA Intern Med · 202487 citationsRCR 13.6
- One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.Acta Psychiatr Scand · 201953 citationsRCR 2.6
- Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study.Clin Neuropharmacol · 200747 citationsRCR 1.4
- Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.Lancet Psychiatry · 201736 citationsRCR 2.2
- Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis: Baseline Results From the TEA Trial.J Clin Psychiatry · 201735 citationsRCR 1.8
- 24 citationsRCR 12.0
- The significance of sampling time in therapeutic drug monitoring of clozapine.Acta Psychiatr Scand · 201722 citationsRCR 1.4
- Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial.J Am Acad Child Adolesc Psychiatry · 201921 citationsRCR 1.4